About
The company has raised an additional USD 8 million from leading investors to facilitate scaling of clinical studies and expansion of commercial international footprint. In the recent AACR (American Association of Cancer Research) meeting, the company presented data from its clinical studies where cResponse was compared to the clinical response of patients for which this data is already available. The test has recently become commercially available in Israel and some private insurance companies cover it for their patients. Curesponse is a cancer precision medicine company whose platform, cResponse, accurately and timely predicts a patient's response to cancer treatment.
Reẖovot